Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Trading 04-22 12:54:10 EDT

57.40

+1.00

+1.77%

High57.90	Low56.35	Vol213.92K
Open56.73	D1 Closing56.40	Amplitude2.75%
Mkt Cap5.48B	Tradable Cap5.16B	Total Shares95.43M
T/O12.24M	T/O Rate0.24%	Tradable Shares89.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":57.4,"timestamp":1776876837576,"preClose":56.4,"halted":0,"volume":213924,"delay":0,"changeRate":0.01773049645390071,"floatShares":89889500,"shares":95427200,"eps":-4.364588,"marketStatus":"Trading","change":1,"latestTime":"04-22 12:54:10 EDT","open":56.73,"high":57.9,"low":56.35,"amount":12242802.706092,"amplitude":0.027482,"askPrice":57.41,"askSize":253,"bidPrice":57.29,"bidSize":208,"shortable":3,"etf":0,"ttmEps":-4.364588,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776888000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":56.4,"preHourTrading":{"tag":"盘前","latestPrice":56.82,"preClose":56.4,"latestTime":"09:29 EDT","volume":7160,"amount":407481.0058,"timestamp":1776864599999,"change":0.42,"changeRate":0.007447,"amplitude":0.046099},"postHourTrading":{"tag":"盘后","latestPrice":56.4,"preClose":56.4,"latestTime":"17:36 EDT","volume":34390,"amount":1939596,"timestamp":1776807393701,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.445063,"impliedVol":0.4334,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/XENE/wiki","defaultTab":"wiki","newsList":[{"id":"2629109209","title":"What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2629109209","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629109209?lang=en_us&edition=fundamental","pubTime":"2026-04-22 14:06","pubTimestamp":1776837979,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus placebo in highly treatment-resistant adult patients.\nMulti-year open-label extension results and real-world survey data highlight azetukalner’s long-term seizure control and the potential practical benefit of a once-daily, no-titration epilepsy therapy for both patients and physicians.\nWith...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SOCL","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274814","title":"Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274814","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628274814?lang=en_us&edition=fundamental","pubTime":"2026-04-20 16:20","pubTimestamp":1776673207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenon (XENE) and Biogen (BIIB) with bullish sentimen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-xenon-xene-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-xenon-xene-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0234570918.USD","BIIB","BK4533","LU0320765992.SGD","BK4112","LU0109394709.USD","BK4588","XENE","LU0889565916.HKD","LABU","IE00B19Z9P08.USD","LU0128526141.USD","BK4585","IE00B19Z9Z06.USD","BLSG","BLSX","BK4139","LU0029874061.USD","XBI","BK4532","BK4137","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628792236","title":"Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2628792236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628792236?lang=en_us&edition=fundamental","pubTime":"2026-04-20 08:46","pubTimestamp":1776645985,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal on...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-presents-data-from-phase-3-x-tole2-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-presents-data-from-phase-3-x-tole2-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE","SOCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628779604","title":"Xenon says Phase 3 X-TOLE2 trial shows azetukalner cuts monthly seizures 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628779604","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628779604?lang=en_us&edition=fundamental","pubTime":"2026-04-20 06:00","pubTimestamp":1776636027,"startTime":"0","endTime":"0","summary":"Xenon presented Phase 3 X-TOLE2 results for azetukalner in focal onset seizures at 2026 AAN Annual Meeting.Trial showed meaningful seizure reduction versus placebo, with more patients reaching complete seizure control as treatment continued through double-blind period.Separate 48-month open-label extension update, also presented at AAN, indicated durable seizure control with a sizable share of patients sustaining long seizure-free periods.Xenon targets FDA New Drug Application submission for azetukalner in Q3 2026, positioning drug for potential first commercial launch in epilepsy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL3mQjRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD","NDAQ","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","XENE","IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628773345","title":"Assessing Xenon Pharmaceuticals (XENE) Valuation After Strong Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2628773345","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628773345?lang=en_us&edition=fundamental","pubTime":"2026-04-18 09:07","pubTimestamp":1776474459,"startTime":"0","endTime":"0","summary":"Key recent performance context for Xenon Pharmaceuticals (XENE)\nXenon Pharmaceuticals (XENE) has drawn attention after a strong share price move, with returns of 8.4% over the past month and 49.3% over the past 3 months, and a last close of US$59.70.\nSee our latest analysis for Xenon Pharmaceuticals.\nThat shorter term momentum sits on top of a stronger backdrop, with a 34.2% year to date share price return and a 70.0% one year total shareholder return suggesting investors have been...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/assessing-xenon-pharmaceuticals-xene-valuation-after-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/assessing-xenon-pharmaceuticals-xene-valuation-after-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627484284","title":"Xenon Pharmaceuticals to present at Bloom Burton healthcare investor conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627484284","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627484284?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:30","pubTimestamp":1776256256,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals will present at Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDLZQqbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","BK4588","XENE","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627463144","title":"Xenon expands 2025 inducement equity plan share reserve to 1,175,000 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627463144","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627463144?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:02","pubTimestamp":1776110570,"startTime":"0","endTime":"0","summary":"Xenon amended and restated its 2025 Inducement Equity Incentive Plan on April 7, 2026.Share reserve under plan increased to 1,175,000 shares from 900,000 shares.Plan covers equity awards such as nonstatutory stock options, restricted stock units, restricted stock.Grants are limited to inducement awards for newly hired employees or rehires following a bona fide employment break.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL3BppT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625276953","title":"Xenon highlights Phase 3 X-TOLE2 azetukalner data in focal onset seizures at AAN 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625276953","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625276953?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:03","pubTimestamp":1775567026,"startTime":"0","endTime":"0","summary":"Xenon flagged Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures for late-breaking presentations at AAN 2026 on April 19.Program update points to positive efficacy and safety profile without detailing performance metrics, keeping azetukalner on track as a potential new option for adults with focal epilepsy.Company also plans to show long-term interim data from X-TOLE open-label extension, extending follow-up to at least 48 months, at AAN 2026 on April 22.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL47HWsK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623392522","title":"How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2623392522","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623392522?lang=en_us&edition=fundamental","pubTime":"2026-03-30 15:08","pubTimestamp":1774854491,"startTime":"0","endTime":"0","summary":"In March 2026, Xenon Pharmaceuticals’ chief medical officer Christopher John Kenney reported a routine, tax-related sale of 1,410 vested restricted stock unit shares, worth about US$78,000, executed under a sell-to-cover instruction.\nThis insider transaction followed Xenon’s positive topline Phase 3 results for lead candidate azetukalner and the completion of an upsized offering of nearly US$750 million, underscoring the company’s progress in both clinical development and capital...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/how-positive-phase-3-azetukalner-results-and-upsized-financi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/how-positive-phase-3-azetukalner-results-and-upsized-financi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XENE","BK4211","ISBC","AIPO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619361463","title":"Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2619361463","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619361463?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:38","pubTimestamp":1773664680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 08:38 ET (12:38 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457513","title":"Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $63 From $64","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457513?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:17","pubTimestamp":1773659841,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40402K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452842","title":"Wedbush Trims Price Target on Xenon Pharmaceuticals to $63 From $64, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452842","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452842?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:54","pubTimestamp":1773658481,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of buy and mean price target of $79.19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619480689","title":"H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619480689","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619480689?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:15","pubTimestamp":1773627316,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Xenon, with a price target of $74.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619723155","title":"Xenon Pharmaceuticals Closes $747.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2619723155","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619723155?lang=en_us&edition=fundamental","pubTime":"2026-03-13 05:45","pubTimestamp":1773351918,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) said late Thursday it has closed its underwritten public offering of 12.2 million common shares, including the full exercise of the overallotment option, and pre-funded warrants to buy up to 877,194 shares, for gross proceeds of $747.5 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619152029","title":"Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619152029","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619152029?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:01","pubTimestamp":1773345660,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, MA, March  12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3255083/33485/en/Xenon-Pharmaceuticals-Announces-Closing-of-747-5-Million-Upsized-Public-Offering-Including-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE","USA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618597413","title":"Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618597413","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618597413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271263,"startTime":"0","endTime":"0","summary":"Ian Mortimer, President and CEO and a director of Xenon Pharmaceuticals Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6W8hRy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon Pharmaceuticals President and CEO Ian Mortimer Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947276","title":"BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Nike, Unifirst","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947276","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947276?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:57","pubTimestamp":1773233879,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Nike, UnifirstWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL6N3ZZ0RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORCX","LU2458330169.SGD","LU0950375773.USD","LU0719512351.SGD","LU0823417737.USD","BK4581","LU0157215616.USD","KALA","BK4528","LU0708994859.HKD","LU1935042991.SGD","LU0786609619.USD","LU0738911758.USD","LU2054465674.USD","SG9999011175.SGD","LU1223082196.USD","IE00BLSP4452.SGD","LU2360106780.USD","ORCL","LU0823417653.USD","LU1720051108.HKD","LU0130102774.USD","LU1642822529.SGD","LU1989772923.USD","IE00BBT3K403.USD","LU0048573561.USD","LU0353189763.USD","LU0314106906.USD","BK4561","BK4213","LU0444973449.USD","LU0256863811.USD","IE00BLSP4239.USD","LU0417517546.SGD","LU0949170772.SGD","LU2250418816.HKD","LU0056508442.USD","BK4566","LU1303367103.USD","SG9999001424.SGD","IE0004445239.USD","LU1366333091.USD","IE00BMPRXQ63.HKD","LU0661504455.SGD","LU0742534661.SGD","LU0861579265.USD","LU2357305700.SGD","LU2506952097.USD","LU1037948541.HKD","LU0109392836.USD","LU0251131958.USD","LU1934455277.USD","LU1989764748.USD","IE0009356076.USD","LU0985489474.SGD","IE0002270589.USD","LU0029864427.USD","CPB","BK4007","SVM","FANG","BK4516","LU0345780281.USD","LU0310800379.SGD","LU1489326972.SGD","LU0965508806.USD","LU1691799644.USD","LU0082616367.USD","LU0476273544.USD","BK4558","BK4588","LU2326559502.SGD","BK4585","LU0648001328.SGD","LU1815336760.USD","LU0823411888.USD","LU1989764664.SGD","IE00B2Q91V27.USD","LU1720051017.SGD","BK4534","LU2746668974.SGD","BK4139","LU1223083913.SGD","LU0234572021.USD","LU1934455194.USD","LU0320765489.SGD","IE00B19Z3581.USD","LU0081259029.USD","LU1037948897.HKD","LU1201861249.SGD","IE00BMPRXR70.SGD","IE00BMPRXN33.USD","LU0348723411.USD","LU0545039389.USD","XENE","IE00BGHQF524.EUR","LU1035773651.USD","BK4137","LU0444971666.USD","BK4570","LU0289960550.SGD","LU0323591593.USD","DTIL","LU2458330243.SGD","LU2237957902.USD","IE00B7SZLL34.SGD","LU1223082519.USD","LU0345780521.USD","LU2236285917.USD","LU1506573853.SGD","BK4543","LU0128525929.USD","IE00BFXG0V08.USD","LU0889565833.HKD","LU1934455863.HKD","LU1548497426.USD","LU2506952170.USD","BK4597","BK4097","LU0234570918.USD","LU0980610538.SGD","LU1267930813.SGD","LU1429558221.USD","LU0889566641.SGD","LU2237957811.SGD","LU1267930573.SGD","SG9999003800.SGD","KOS","LU0878866978.SGD","BK4212","BK4210","LU1069347547.HKD","LU1803068979.SGD","UNF","IE00BYQQ9H92.USD","LU0208291251.USD","BK4146","IE00B19Z3B42.SGD","IE00B3S45H60.SGD","LU0210536198.USD","LU2896262040.SGD","LU2506951958.HKD","LU2860962120.EUR","LU1935042215.USD","LU1935043023.USD","LU1935043536.SGD","LU0965509283.SGD","LU0068578508.USD","LU0070302665.USD","LU2087625088.SGD","CDE","IE00BN8TJ469.HKD","LU0553294199.USD","LU2506951875.HKD","NKE","HL","LU0433182093.SGD","LU0965509010.AUD","LU0198837287.USD","LU1366192091.USD","LU2108987350.USD","ORCS","LU0965509101.SGD","LU0792757196.USD","LU0957808578.USD","LU1003077747.HKD","LU2746668461.USD","LU1852331112.SGD","IE00B775SV38.USD","BK4533","LU0251142724.SGD","LU1435385759.SGD","BK4017","BK4538","LU2098885051.SGD","ORCU","LU1935042488.USD","LU0175139822.USD","IE00B3CCJ963.GBP","LU0353189680.USD","LU1989772840.SGD","IE00B5949003.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618394345","title":"Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2618394345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618394345?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:00","pubTimestamp":1773223216,"startTime":"0","endTime":"0","summary":"The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Bla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-10-5m-share-spot-secondary-priced-at-57-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-10-5m-share-spot-secondary-priced-at-57-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BLSP4239.USD","LU2430703251.USD","LU0256863811.USD","LU1496350171.SGD","XENE","LU1064131342.USD","BK4534","LU2417539215.USD","LU0868494617.USD","LU2552382132.HKD","LU0868494708.USD","LU0211331839.USD","BK4566","IE00BJTD4N35.SGD","LU0820561909.HKD","LU2505996509.AUD","LU0345769128.USD","LU0170899867.USD","LU2106854487.HKD","IE00BJLML261.HKD","BK4533","LU1548497426.USD","LU0323591593.USD","LU0787776722.HKD","LU0345770993.USD","LU1551013425.SGD","LU0211328371.USD","LU1244550494.USD","IE00BBT3K403.USD","LU1917777945.USD","IE00BKVL7J92.USD","LU0964807845.USD","BK4581","LU0006306889.USD","LU0203347892.USD","JPMO","IE00B1XK9C88.USD","LU0820561818.USD","LU0070302665.USD","LU0820562030.AUD","LU2552382215.SGD","LU0215105999.USD","LU0345770308.USD","LU1914381329.SGD","LU2237443465.HKD","LU2592432038.USD","LU0238689110.USD","LU2756315318.SGD","LU2213496289.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618999137","title":"Xenon Pharmaceuticals prices upsized USD 650 million public offering at USD 57 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2618999137","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618999137?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:39","pubTimestamp":1773196788,"startTime":"0","endTime":"0","summary":"Xenon priced an upsized underwritten public offering of 10.53 million common shares at USD 57 per share. The offering also includes pre-funded warrants to purchase up to 0.88 million common shares at USD 57 per warrant. Gross proceeds are expected to be about USD 650 million, before underwriting discounts and offering expenses. The underwriters have a 30-day option to buy up to 1.71 million additional common shares at the public offering price. A preliminary prospectus supplement and accompanying prospectus were filed with the SEC and are available at www.sec.gov.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL61rHj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","XENE","SG9999014005.SGD","BK4112","BK4588","BK4139","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618991347","title":"Xenon Pharmaceuticals Inc - Common Shares Offered at $57.00 per Share; Pre-Funded Warrants at $56.9999","url":"https://stock-news.laohu8.com/highlight/detail?id=2618991347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618991347?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:39","pubTimestamp":1773196772,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA503XH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com;investor.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0497},{"period":"1month","weight":0.0266},{"period":"3month","weight":0.3756},{"period":"6month","weight":0.3689},{"period":"1year","weight":0.6254},{"period":"ytd","weight":0.2584}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.0273},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.3701},{"period":"ytd","weight":0.0325}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.076063},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040327},{"month":4,"riseRate":0.5,"avgChangeRate":0.018478},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.037416},{"month":6,"riseRate":0.454545,"avgChangeRate":0.032291},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction